Ivan S. Sadovskiy

Ivan S. Sadovskiy

Auto-generated profile, based on publicly available information

Ivan S. Sadovskiy

Federal Research Center “Krasnoyarsk Science Center” of the Siberian Branch of the Russian Academy of Sciences

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2022 in Russian Journal of Immunology
Verified
Journal Article
Open access
PDF file
Complex inflammation indexes in patients with post-COVID syndromeНа сегодняшний день в мире активно занимаются выделением новых маркеров, характеризующих тяжесть состояния после перенесенного COVID-19. Для более детального понимания того, какие изменения вызывает вирус SARS-CoV-2 в организме человека и с чем взаимосвязано длительное сохранение симптомов после перенесенной новой коронавирусной инфекции, необходимо оценить связь между степенью тяжести после заболевания и показателями клинического анализа крови. Цель работы – выделение прогностических маркеров по клиническому анализу крови, коррелирующих с тяжестью состояния пациентов после перенесенной новой коронавирусной инфекции. В исследование включены 372 пациента в постковидный период. Исходное течение заболевания оценивалось с использованием шкалы клинического прогрессирования ВОЗ. Разделение пациентов на группы осуществлялось по шкале функционального состояния после COVID-19 (PCFS). В анализе крови обследуемых были выделены критические значения лабораторных показателей, которые были проанализированы на предмет наличия взаимосвязей с тяжестью синдрома. Проведен качественный анализ типов реакции иммунной системы в программе «Протист». Установлены наиболее статистически выраженные изменения у пациентов группы 1. Коэффициенты NLR, LMR, SII при сравнении с группой пациентов 1, 2, 3 были ниже. Индекс PLR был ниже при сравнении с группой пациентов 0. Других статистических различий между группами не выявлено. Поэтому интерес вызывает исследования качественных показателей. В группах больных 0, 1, 2 в основном определяется ареактивность иммунитета (71-92%), а в группах пациентов 3 и 4 уже у половины...
ISIvan S. Sadovskiy
Ivan S. Sadovskiy
OKOlga S. Kruglova
Olga S. Kruglova
ASAndrei Savchenko
Andrei Savchenko
ESElena A. Sobko
Elena A. Sobko
EKEdward V. Kasparov
Edward V. Kasparov
ABAlexandr G. Borisov
Alexandr G. Borisov
Today, the world is actively engaged in the selection of new markers that correlate with severity of the condition after recovery from COVID-19. For a more detailed understanding of the changes caused by SARS-CoV-2 virus in the human body, and assessment of the factors correlating with long-term persistence of symptoms after a new coronavirus infection, one should evaluate the relationships between the severity of the disease and the indices of clinical and biochemical blood tests. The purpose of the work was to reveal prognostic markers based on clinical blood testing which correlate with severity of the patients condition after a new coronavirus infection. The study included 372 patients in the post-COVID period. Initial course of the disease was assessed using the WHO Clinical Progression Scale. The patients were divided into groups according to the Post-COVID-19 Functional Status Scale (PCFS). When performing clinical blood analysis of subjects, critical points of laboratory parameters were identified and analyzed for presence of relationships with severity of the syndrome. Qualitative analysis of distinct types of immune reactions was carried out using the Protist software. The more pronounced statistically significant changes were found for the group 1. The NLR, LMR, SII coefficients were lower when compared with group 1, 2, 3. The PLR index was lower when compared with group 0. There were no other statistical differences between the groups. Therefore, the study of qualitative indexes is of interest. Suppressed immune respose (71-92%) was revealed, mainly, in groups 0, 1, 2. Activation of innate immunity, increased adaptive immunity and immunodeficiency (immune suppression) in groups 3 and 4 are observed in a half of the cases. The patients from group 2 took an intermediate position. Over the post-COVID period, general hematological disorders are not pronounced and sufficient for making a diagnosis. Therefore, one should bring more attention to complex qualitative indicators. It makes sense to use the Methods for determining the type of immune response by a comprehensive blood test as one of the main qualitative parameters in patients in the post-COVID period. At the same time, assessing the type of immune response allows not only to identify patients with post-COVID syndrome, but also to select patients who require anti-inflammatory and detoxication therapy.

1 January 2022 in Infectious diseases: News, Opinions, Training
Verified
Journal Article
Closed access
ETE.P. Tikhonova
E.P. Tikhonova
ASAndrei Savchenko
Andrei Savchenko
TYT.A. Yelistratova
T.A. Yelistratova
YKYu.S. Kalinina
Yu.S. Kalinina
TKT.Yu. Kuz'Mina
T.Yu. Kuz'Mina
ABA.G. Borisov
A.G. Borisov
Влияние этиотропной терапии на формирование иммунных нарушений у пациентов с COVID-19

16 February 2025 in Russian Journal of Immunology
Verified
Journal Article
Open access
PDF file
ISI. S. Sadowski
I. S. Sadowski
OKO. S. Kruglova
O. S. Kruglova
ASA. A. Savchenko
A. A. Savchenko
ESE. A. Sobko
E. A. Sobko
EKE. V. Kasparov
E. V. Kasparov
ABA. G. Borisov
A. G. Borisov
The COVID-19 pandemic, which began in December 2019, was caused by the new coronavirus SARS-CoV-2. SARS-CoV-2 is a shell virus containing a single positive chain genome and using angiotensin converting enzyme 2 (ACE2) as a cell entry receptor. The targeting of SARS-CoV-2 on several tissues expressing ACE2 explains the multifactorial pattern of symptoms: fever, dry cough, myalgia, fatigue and shortness of breath. These symptoms do not always stop after COVID-19, and symptoms may reappear within 12 weeks, which indicates the development of post-COVID syndrome (long COVID). Due to the extensive symptoms and comorbidity of patients, the clinical diagnosis of post-COVID syndrome is difficult. The aim of the study is to identify pathognomonic indices of biochemical blood analysis in convalescents, indicating the development of post-COVID syndrome. Patients and study design: a retrospective observational one-moment study of 373 case histories and outpatient records was conducted for the patients exposed to COVID-19 not later than 12 weeks ago. The initial course of the disease (disease) was assessed using the WHO Clinical Progression Scale. The severity of post-COVID syndrome (clinical outcomes) was assessed on the functional status scale after COVID-19 (PCFS). All subjects are divided into four groups, the names of which reflect the severity of COVID-19 and the severity of the post-ovoid condition: 1st group, “mild COVID-19 / 0-2 PCFS class”; 2nd group, “mild COVID-19 / 3-4 PCFS class”; 3rd group, “medium and severe COVID-19 / 0-2 PCFS class”; 4th group, “medium and severe COVID-19 / 3-4 PCFS class”. The sample was described by calculating the median (Me) values and interquartile range expressed as Q1 and Q3 (Q0.25-Q0.75). The reliability of the differences between independent samples was assessed with nonparametric Mann–Whitney U-test and the Student’s t-test. Upon evaluation of clinical blood biochemistry, the alanine aminotransferase (ALT) level in group 1 was higher than in groups 2 and 4, the aspartate aminotrasferase (AST) level in group 2 was higher than in groups 1 and 3. The indexes of total cholesterol and LDL did not show statistically significant differences between the groups. Creatinine levels in group 3 are higher than in group 1, being lower in group 4 than in other groups. Significant differences were observed upon qualitative assessment of C-reactive protein (CRP). There were 2-3 times more subjects with elevated CRP levels in groups 2 and 4 than in group 1. A minimal biochemical profile, including an assessment of the level of transaminases and creatinine, a qualitative or quantitative assessment of C-reactive protein, may indicate development of chronic inflammation. Patients of this group need to undergo an additional examination, e.g., general urine analysis and determination of albumin level in urine, dynamic GFR calculation, in order to prevent the development of persistent renal impairment.

4 September 2024 in Cytokines and inflammation
Verified
Journal Article
Closed access
PDF file
ABAlexander G. Borisov
Alexander G. Borisov
SBSnezhana V. Bychkovskaya
Snezhana V. Bychkovskaya
APAndrey P. Prodeus
Andrey P. Prodeus
SSSvetlana V. Smirnova
Svetlana V. Smirnova
TGTatyana A. Gerasimova
Tatyana A. Gerasimova
МЗМархайчук Айшат Зиябутдиновна
Мархайчук Айшат Зиябутдиновна
BACKGROUND: According to data from the World Health Organisation, up to 40% of the world’s population and up to 35% of the Russian population suffer from allergies. Assessing the impact of the exposome in the population of the Russian Federation is a crucial issue of national public health care, which will provide a personalised approach to the treatment and prevention of allergic diseases in the local population. AIM: To evaluate the sensitisation profile in children with allergic diseases from different regions of Russia. MATERIALS AND METHODS: The study included sick children aged 2 to 12 years with allergic manifestations from different regions of the Russian Federation. The concentration of total IgE and allergen-specific immunoglobulins in blood was determined retrospectively on the basis of analyses of results obtained in clinical and diagnostic laboratories performing immunoblotting tests using the Allergy-Q® test system (South Korea). RESULTS: Sensitisation to allergens mediated by IgE was detected more frequently than in half of the cases (436 people — 58.39%). In the group of household allergens the first place is occupied by cat, then dog and already then house dust. Among respiratory allergens, birch and/or other trees, weeds and mugwort are the leaders. Food sensitisation in children is mainly to milk, egg, fish and seafood. CONCLUSIONS: The peculiarities of sensitisation revealed in different regions are easily explained by the formed exposomes (due to different climatic conditions, peculiarities of regional vegetation and nutrition). The obtained data can be used to develop measures of prevention, diagnosis and treatment of allergic diseases.

21 July 2026 in Russian Journal of Infection and Immunity
Verified
Journal Article
Open access
PDF file
ISIvan S. Sadowski
Ivan S. Sadowski
СССадовский Иван Сергеевич
Садовский Иван Сергеевич
ASA. A. Savchenko
A. A. Savchenko
САСавченко А. А.
Савченко А. А.
EKE. V. Kasparov
E. V. Kasparov
БГБорисов А. Г.
Борисов А. Г.
Introduction. Post-COVID syndrome (PCS), which develops in 10–35% of cases, is characterized by a spectrum of persistent symptoms sustained for more than 12 weeks post-acute SARS-CoV-2 infection. The aim of the study was to characterize the clinical blood test in patients with varying PCS severity and determine a risk of its development in comorbid pathology while assessing a relation between COVID-19 severity and PCS. Materials and methods. Medical records from 373 patients who underwent an in-depth dispensary examination not earlier than 12 weeks following COVID-19 was conducted at the clinic of the Research Institute of Medical Problems of the North and the Krasnoyarsk Regional Clinical Hospital (Krasnoyarsk). COVID-19 severity was assessed using the WHO Clinical Progression Scale (WHO-CPS). PCS general characteristics were assessed using the Post-COVID-19 Functional Status Scale (PCFS). Comorbidity was assessed using the Age-Specific Charlson Comorbidity Index (ACCI). The type and characteristics of the immune response were assessed using the PROTIST software. Results. The ACCI index in individuals with moderate and severe COVID-19/moderate and severe PCS was significantly higher than in groups without PCS and with mild COVID-19/mild PCS. In patients who had moderate/severe COVID-19, the development of moderate/severe PCS was accompanied by elevated CRP level in 34.5% of cases (20 patients), a peaked rate among all groups. In the group with moderate and severe COVID-19/moderate and severe PCS, the leukocyte level is lower than in group without PCS, but higher than in group with mild COVID-19/mild PCS. The absolute granulocyte level in this group is higher than in other groups. Conclusion. It has been found out that COVID-19 severity is a prognostic factor for PCS development. While assessing immune response types, it was found that more than 50% of patients with moderate/severe PCS show activated innate immunity, while only 25% were non-reactive/normal. The presence of these PCS phenotypes underlies a need for a personalized approach while recommending anti-inflammatory therapy.

4 September 2024 in Cytokines and inflammation
Verified
Journal Article
Open access
PDF file
ASAndrei Savchenko
Andrei Savchenko
Igor KudryavtsevIgor Kudryavtsev
Igor Kudryavtsev
DIDmitry V. Isakov
Dmitry V. Isakov
ISIvan S. Sadowski
Ivan S. Sadowski
Vassiliy BelenyukVassiliy Belenyuk
Vassiliy Belenyuk
Vassiliy BelenyukVassiliy Belenyuk
Vassiliy Belenyuk
Post-COVID syndrome develops in 10–20% of people who have recovered from COVID-19 and it is characterized by impaired function of the nervous, cardiovascular, and immune systems. Previously, it was found that patients who recovered from infection with the SARS-CoV-2 virus had a decrease in the number and functional activity of NK cells. The aim of the study was to assess the effectiveness of recombinant human interleukin-2 administered to correct NK cell phenotype and functional activity in patients with post-COVID syndrome. Patients were examined after 3 months for acute COVID-19 of varying severity. The phenotype of the peripheral blood NK cells was studied by flow cytometry. It was found that disturbances in the cell subset composition in patients with post-COVID syndrome were characterized by low levels of mature (p=0.001) and cytotoxic NK cells (p=0.013), with increased release of immature NK cells (p=0.023). Functional deficiency of NK cells in post-COVID syndrome was characterized by lowered cytotoxic activity due to the decreased count of CD57+ (p=0.001) and CD8+ (p 0.001) NK cells. In the treatment of patients with post-COVID syndrome with recombinant human interleukin-2, peripheral blood NK cell count and functional potential were restored. In general, the effectiveness of using recombinant human interleukin in treatment of post-COVID syndrome has been proven in patients with low levels of NK cells. This article is a translation of the article by Savchenko AA, Kudryavtsev IV, Isakov DV, Sadowski IS, Belenyuk VD, Borisov AG. Recombinant Human Interleukin-2 Corrects NK Cell Phenotype and Functional Activity in Patients with Post-COVID Syndrome. Pharmaceuticals. 2023;16(4):537. DOI: 10.3390/ph16040537 Published with the permission of the copyright holder.